<DOC>
	<DOCNO>NCT01619683</DOCNO>
	<brief_summary>To determine effect 12 month treatment Androxal bone mineral density men secondary hypogonadism .</brief_summary>
	<brief_title>Assessment Effects Enclomiphene Citrate Bone Mineral Density Men With Secondary Hypogonadism</brief_title>
	<detailed_description>This study phase III single-blind placebo-controlled safety study 52 week active dosing period Androxal . Safety assess physical visual acuity exam , slit lamp fundoscopy eye exam , clinical laboratory test , DEXA scanning , lean soft tissue assessment ( LST ) , adverse event reporting . Results compare age-matched placebo group .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Overweight ( BMI 25 42 kg/m2 inclusive , BMI 23 42 inclusive Asian subject ) male age 18 60 inclusive 2 . Men currently use topical testosterone product washout least 7 day Visit 1 3 . All clinical laboratory test within normal range ( clinically significant deviation laboratory result require approval sponsor ) 4 . Previously concurrently diagnose secondary hypogonadism confirm morning testosterone &lt; 300ng/dL measure twice separate day . One two TT level must confirm baseline . Subjects fail criterion enrol placebo group . 5 . LH &lt; 9.4 mIU/mL ( Visit 1 ) 6 . Ability complete study compliance protocol 7 . Ability understand provide write informed consent 1 . Use injectable pelleted testosterone within 6 month prior study ( men currently topical product may enrol study 7day washout period ) 2 . Use testosterone injection , spironolactone , cimetidine , Clomid , 5Î±reductase inhibitor , hCG , androgen , estrogen , anabolic steroid , DHEA , herbal hormone product study 3 . Use Clomid past year 4 . Uncontrolled hypertension diabetes mellitus base Investigator 's assessment baseline . Subjects treat Type II diabetes allow study . Newly diagnose diabetic need treat least 48 hour enrol study 5 . Clinically significant abnormal finding screen ( Visit 1 ) , base Investigator 's assessment . 6 . A hematocrit &gt; 54 % hemoglobin &gt; 17 g/dL 7 . Clinically significant abnormal laboratory finding baseline ( Visit 2 ) , base Investigator 's assessment 8 . Use investigational drug product , participation drug medical device research study within 30 day prior receive study medication . 9 . Known hypersensitivity Clomid 10 . Symptomatic cataract ( nuclear sclerosis cataract cortical cataract grade &gt; 2 base 04 scale trace posterior subcapsular cataract ) 11 . Abnormal fundoscopy exam central retinal vein occlusion 12 . Any condition opinion investigator would interfere participant 's ability provide inform consent , comply study instruction , possibly confound interpretation study result , endanger participant take part study 13 . Irreversibly infertile compromise fertility ( cryptorchism , Kallman Syndrome , primary hypogonadism , tumor pituitary ) 14 . Current history breast cancer 15 . Subjects Zscore &lt; 2 16 . Hyperparathyroidism , metabolic bone disease , previous fracture spine , recent chemotherapy , use medication may influence BMD ( thyroid replacement therapy , immunosuppressive therapy , prednisone antiepileptic drug 17 . No intravenous oral contrast agent within 7 day . 18 . Subject weigh &gt; 300 pound ( &gt; 136 kg ) 19 . Current history prostate cancer suspicion prostate disease unless rule prostate biopsy , PSA &gt; 3.6 20 . Presence history know hyperprolactinemia without tumor 21 . Chronic use medication use glucocorticoid 22 . History drug abuse chronic narcotic use include methadone 23 . Subjects know history HIV and/or Hepatitis C 24 . Subjects end stage renal disease 25 . Subjects cystic fibrosis ( mutation CFTR gene ) 26 . Enrollment previous Androxal study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>